NCT05186623 Prediction Model for Response to Biologics and Small Molecular Agent for UC
| NCT ID | NCT05186623 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Asan Medical Center |
| Condition | Ulcerative Colitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2022-02-05 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2022-02-05 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective observational study is going to develop and validate a prediction model of response to biologic agents and small molecular agents for Korean patients with ulcerative colitis.
Eligibility Criteria
Inclusion Criteria: * Patients with an established diagnosis of ulcerative colitis based on clinical symptoms, endoscopic features and histopathologic features * Patients who are going to receive vedolizumab, ustekinumab, or tofacitinib treatment Exclusion Criteria: * Not Korean ethnicity by family history * Inflammatory Bowel Disease Unclassified * Patients who already received colectomy due to ulcerative colitis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05186623 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 79 Years, studying Ulcerative Colitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05186623 currently recruiting?
Yes, NCT05186623 is actively recruiting participants. Contact the research team at bdye@amc.seoul.kr for enrollment information.
Where is the NCT05186623 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT05186623 clinical trial?
NCT05186623 is sponsored by Asan Medical Center. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.